Targeting Disease with B-Tech

ILiAD's B-Tech program integrates validated proprietary technology to develop therapeutics for the prevention and treatment of disease. BPZE1 is the most advanced ILiAD clinical candidate developed using B-Tech.

In addition to BPZE1, the B-Tech program includes the B-Tech Vector platform with the potential to deliver a range of pathogen and immuno-oncology antigens to mucosal tissue to allow for the induction of protective immunity.

---